Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (formerly Xcyte Therapies, Inc.) on May 16, 2006. The filing serves to provide historical financial statements of Cyclacel Limited, a subsidiary acquired in a transaction completed on March 27, 2006, pursuant to a Stock Purchase Agreement dated December 15, 2005. These statements are required in connection with the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2006.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a cover for the submission of historical audited financial statements (Exhibit 99.1) rather than containing the financial data itself.
Material Changes
The primary material event referenced is the completion of the acquisition of Cyclacel Limited on March 27, 2006. This filing amends a previous Form 8-K filed on March 30, 2006, to include the required financial statements of the acquired entity.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors. It notes that the amendment to include the full required financial statements will be filed no later than June 6, 2006. The purpose of this specific filing is to assist investors in reviewing the Company's quarterly report filed on May 15, 2006.
Investor Verification Checklist
- Verify the contents of Exhibit 99.1 for the actual historical audited financial statements of Cyclacel Limited.
- Review the Form 10-Q filed on May 15, 2006, for the consolidated financial impact of the acquisition.
- Confirm the filing of the amended Form 8-K by June 6, 2006, as stated in the report.
- Check the Stock Purchase Agreement dated December 15, 2005, for terms of the acquisition.